Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Innovative OSA Solution | Nyxoah's Genio device offers unique features for obstructive sleep apnea treatment, targeting a $34 billion market opportunity across key regions |
Financial Crossroads | Explore Nyxoah's mixed financial performance, with recent European market challenges offset by preparations for a crucial U.S. market entry |
Regulatory Milestones | Learn about Nyxoah's progress towards FDA approval, with potential U.S. launch in late 2024 or early 2025 marking a pivotal growth phase |
Market Dynamics | Analyst price targets range from $16 to $20, reflecting optimism about Nyxoah's potential to disrupt the OSA treatment landscape despite competition |
Metrics to compare | NYXH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNYXHPeersSector | |
---|---|---|---|---|
P/E Ratio | −5.4x | −0.9x | −0.7x | |
PEG Ratio | 1.61 | −0.03 | 0.00 | |
Price/Book | 2.7x | 2.2x | 2.6x | |
Price / LTM Sales | 56.7x | 4.7x | 3.2x | |
Upside (Analyst Target) | 95.8% | 108.8% | 43.2% | |
Fair Value Upside | Unlock | 14.6% | 6.8% | Unlock |